BTW
NVO

Boston Trust Walden’s Novo Nordisk NVO Stock Holding History

Boston Trust Walden’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$580K Buy
12,091
+55
+0.5% +$2.36K ﹤0.01% 327
2026
Q1 		$442K Hold
12,036
– – ﹤0.01% 340
2025
Q4 		$612K Hold
12,036
– – ﹤0.01% 313
2025
Q3 		$668K Hold
12,036
– – ﹤0.01% 308
2025
Q2 		$831K Buy
12,036
+6,670
+124% +$454K 0.01% 287
2025
Q1 		$373K Hold
5,366
– – ﹤0.01% 333
2024
Q4 		$462K Hold
5,366
– – ﹤0.01% 320
2024
Q3 		$639K Hold
5,366
– – ﹤0.01% 308
2024
Q2 		$766K Hold
5,366
– – 0.01% 292
2024
Q1 		$689K Sell
5,366
-13,980
-72% -$1.66M ﹤0.01% 302
2023
Q4 		$2M Hold
19,346
– – 0.02% 246
2023
Q3 		$1.76M Hold
19,346
– – 0.01% 251
2023
Q2 		$1.57M Buy
19,346
+1,000
+5% +$81.7K 0.01% 257
2023
Q1 		$1.46M Sell
18,346
-400
-2% -$28.4K 0.01% 255
2022
Q4 		$1.27M Sell
18,746
-184
-1% -$10.8K 0.01% 267
2022
Q3 		$943K Hold
18,930
– – 0.01% 275
2022
Q2 		$1.05M Sell
18,930
-100
-0.5% -$5.55K 0.01% 272
2022
Q1 		$1.06M Sell
19,030
-100
-0.5% -$5.13K 0.01% 277
2021
Q4 		$1.07M Sell
19,130
-100
-0.5% -$5.42K 0.01% 282
2021
Q3 		$923K Buy
19,230
+1,100
+6% +$53.2K 0.01% 287
2021
Q2 		$759K Buy
18,130
+250
+1% +$9.69K 0.01% 299
2021
Q1 		$603K Buy
17,880
+550
+3% +$19.6K 0.01% 310
2020
Q4 		$605K Hold
17,330
– – 0.01% 307
2020
Q3 		$602K Hold
17,330
– – 0.01% 304
2020
Q2 		$567K Hold
17,330
– – 0.01% 305
2020
Q1 		$522K Sell
17,330
-190
-1% -$5.66K 0.01% 302
2019
Q4 		$507K Buy
17,520
+2,190
+14% +$60.6K 0.01% 322
2019
Q3 		$396K Hold
15,330
– – 0.01% 336
2019
Q2 		$391K Hold
15,330
– – 0.01% 339
2019
Q1 		$401K Sell
15,330
-70
-0.5% -$1.72K 0.01% 343
2018
Q4 		$355K Sell
15,400
-3,350
-18% -$74.4K 0.01% 341
2018
Q3 		$442K Hold
18,750
– – 0.01% 339
2018
Q2 		$432K Sell
18,750
-900
-5% -$21.4K 0.01% 339
2018
Q1 		$484K Buy
19,650
+3,200
+19% +$84K 0.01% 335
2017
Q4 		$441K Buy
+16,450
New +$418K 0.01% 343
2015
Q3 		– Sell
-9,700
Closed -$266K – 355
2015
Q2 		$266K Buy
9,700
+2,200
+29% +$61.8K ﹤0.01% 338
2015
Q1 		$200K Buy
+7,500
New +$173K ﹤0.01% 339

Other funds holding NVO

SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
AIIMS
Analyst IMS Investment Management Services Tel-Aviv, Israel $4.3B AUM 37.33% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
GIM
Generate Investment Management Auckland, New Zealand $2.43B AUM 37.24% 1-Year Est. Return
CFB
Cullen/Frost Bankers San Antonio, Texas $10.1B AUM 29.18% 1-Year Est. Return

Boston Trust Walden's NVO Position: Q2 2026 in Review

Boston Trust Walden increased its Novo Nordisk (NVO) stake by 0.46% in Q2 2026, buying an estimated $2.36K and bringing the position to 12,091 shares worth $580K. The position accounts for ﹤0.01% of the portfolio, ranked #327.

Boston Trust Walden first reported a position in NVO in Q1 2015 and has held it in 37 quarters since. The position peaked at $2M in Q4 2023. 539 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Boston Trust Walden held 12,091 shares of Novo Nordisk worth $580K as of Q2 2026.
  • Boston Trust Walden bought 55 Novo Nordisk shares in Q2 2026, an estimated $2.36K.
  • Novo Nordisk made up ﹤0.01% of Boston Trust Walden's portfolio in Q2 2026, its #327 holding.
  • Boston Trust Walden first reported a position in Novo Nordisk in Q1 2015 and has held it in 37 quarters since.
  • Boston Trust Walden's Novo Nordisk position peaked at $2M in Q4 2023.
  • 539 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Boston Trust Walden's 13F filing for Q2 2026, filed 24 Jul 2026.